Abstract: The invention relates to a method and to an apparatus for recognizing tumorous living cell tissue. It furthermore relates to a method and to an apparatus for recognizing tumorous cell tissue at collected living cell tissue samples. In the method, electromagnetic radiation is emitted with local definition onto cell tissue by a radiation source and, after deactivation of the radiation source, the decay behavior of the inherent fluorescence intensity of the cell tissue excited by the electromagnetic radiation is detected at the cell tissue in a time resolved and spectrally resolved manner at known sampling rate(s) for at least one wavelength using a detector.

Abstract: In a mammography apparatus, a deflection of an x-ray source aligned on a radiation detector is predetermined depending on the size of a breast compressed in the compression unit and/or the density of the breast tissue. Given an increasing deflection on an arc-shaped trajectory of the x-ray source, the compression of the breast is reduced at least once so that the path of the x-rays through the breast stays within a predetermined path length, starting from a first compression in a first x-ray acquisition.

Abstract: A medical instrument is provided for use with a phase contrast imaging. The medical instrument includes at least one component, which has a strong small angle scattering of x-rays. Furthermore, a corresponding x-ray recording system with phase contrast imaging for recording an examination object may include such a medical instrument.

Abstract: In this device and the associated method, a connection unit that can be attached to an arm bearing an x-ray source and an x-ray receiver is fashioned such that said connection unit compensates for a pivot movement of the arm so that a compression unit arranged at the connection unit remains stationary during a pivot movement.

Abstract: A system includes at least one device that includes at least one device component. For a defined movement of the at least one device component, a movement axis and/or a movement direction may be selected by a selection element and may be identified by an activatable lighting element. The identified movement axis and/or the identified movement direction may be released by at least one actuation element, so that a desired movement of the at least one device component may be performed.

Abstract: In a method and apparatus for detecting tumorous cell tissue in a gastrointestinal tract, electromagnetic radiation is emitted in a locally defined manner from an endoscope onto cell tissue and, after deactivation of the radiation, the decay of the inherent fluorescence intensity of the irradiated cell tissue, excited by the electromagnetic radiation, is detected, with temporal and spectral resolution and with a known scanning rate for at least one wavelength. From the intensity measurement values obtained in this manner, the difference autocorrelation function of the intensity decay is determined, from which a fractal dimension for the irradiated cell tissue is determined. The value of the fractal dimension is used to classify the irradiated cell tissue as to a degree to which the cell tissue is tumorous.

Abstract: In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.

Abstract: The invention relates to a method and to an apparatus for recognizing tumorous living cell tissue. It furthermore relates to a method and to an apparatus for recognizing tumorous cell tissue at collected living cell tissue samples. In the method, electromagnetic radiation is emitted with local definition onto cell tissue by a radiation source and, after deactivation of the radiation source, the decay behavior of the inherent fluorescence intensity of the cell tissue excited by the electromagnetic radiation is detected at the cell tissue in a time resolved and spectrally resolved manner at known sampling rate(s) for at least one wavelength using a detector.

Abstract: In a method for treating a carcinoma in a patient, a medicine is administered via the blood stream of the patient that appears, to the patient's immune system, that tissue of the carcinoma is an inflammation source. The medicine employs two active components that are coupled to each other in a form allowing administration of the two active components to the carcinoma via the blood stream of the patient. A first of the active components is at least one coupling molecule that specifically tethers to a target molecule formed by cancer tissue of the carcinoma. A second of the active ingredients is at least one signal molecule typical to inflammation, or at least one originating molecule encoding such a signal molecule, that induces the immune system of the body to attack the cancer cells.

Abstract: In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.

Abstract: In order to determine the aggressiveness of a prostate tumor, a diagnostic substance is administered to a patient that includes a biomarker provided with a first label that is detectable with a detection device and that specifically binds to a VEGF molecule, and that contains a biomarker that binds specifically to a target molecule that occurs uniformly in the endothelium of blood vessels of healthy tissue and the blood vessels of a prostate tumor, and that is provided with a second label that is detectable with the detection device independently of the first label.

Abstract: In a shockwave system with a shockwave source for treatment of a patient with shockwaves, a control and evaluation unit for evaluating an input signal supplied directly thereto that is correlated with a blood pressure value of the patient determined during the treatment, and controls the shockwave source dependent on the input signal.

Abstract: A urological x-ray workstation has an x-ray source and an x-ray receiver that are respectively supported on device retainers of a device carrier located at the longitudinal side of a patient positioning table such that they can be positioned opposite one another and independently of one another in various positions on an orbit proceeding around a common center in a working plane oriented perpendicular to the longitudinal axis.

Abstract: In a method for image guided prostate cancer needle biopsy, a first registration is performed to match a first image of a prostate to a second image of the prostate. Third images of the prostate are acquired and compounded into a three-dimensional (3D) image. The prostate in the compounded 3D image is segmented to show its border. A second registration and then a third registration different from the second registration is performed on distance maps generated from the prostate borders of the first image and the compounded 3D image, wherein the first and second registrations are based on a biomechanical property of the prostate. A region of interest in the first image is mapped to the compounded 3D image or a fourth image of the prostate acquired with the second modality.

Abstract: In a method and medical apparatus to determine a tumor characteristic related to a body region of a patient, the body region is exposed to acoustic energy that mechanically irritates the body region. A first value of a characteristic value of the patient that is correlated with the irritation is determined at a first point in time. A second value of the characteristic value is determined at a second point in time after the first point in time and after the exposure. The tumor characteristic is determined from the change between first value and second value.

Abstract: A diagnostic substance for use in a method for diagnosing prostate diseases contains multiple different coupling molecules that respectively bind to signal molecules (target molecules) of a molecular surface structure of a pathological tissue that is associated with a prostate disease. A first of the coupling molecules specifically binds to signal molecules of cancer tissue, and a second of the coupling molecules specifically binds to signal molecules formed in inflamed tissue. First and second markers are respectively associated with the first and second coupling molecules, the first and second markers being detectable, and differentiated from each other, with a detection device.

Abstract: In a method to determine at least one parameter pertaining to a prostate of a patient, an integrated diagnostic support system implements the following steps. A first risk value for prostate illness is determined using a screening method. In the event that this first characteristic risk value exceeds a first limit value, at least one second characteristic risk value for prostate illness and its location are determined using a method supplying a medical image of the patient. An integrated report system outputs at least one of the characteristic risk values and/or the location. A corresponding device has a mini-laboratory analysis unit for the screening test, an intelligent decision support system for the first characteristic risk value, a first interface with an imaging system, an evaluation system for the medical image for the second characteristic risk value, and a report system with a user interface.

Abstract: A urological x-ray workstation has an x-ray source and an x-ray receiver that are respectively supported on device retainers of a device carrier located at the longitudinal side of a patient positioning table such that they can be positioned opposite one another and independently of one another in various positions on an orbit proceeding around a common center in a working plane oriented perpendicular to the longitudinal axis.

Abstract: In a method and a device for x-ray brachytherapy, a probe is inserted into the interior of the body of a subject, the probe carrying at its distal end an x-ray source that radiates x-rays into an exposure area in the body of the subject outside of the probe. The probe also contains an x-ray array that generates an ultrasound image representing at least a portion of the exposure area. A display device displays the ultrasound image to allow identification of the exposure area in the ultrasound image.

Abstract: The invention concerns a medicine for treatment of prostate cancer and a corresponding treatment method. The medicine can be supplied to a prostate tumor through the bloodstream, contains an active component and a binding component as well as ultrasound microbubbles. The binding component includes coupling molecules that specifically bind to a determined target molecule formed in the endothelium of tumor-associated blood vessels and that is typical of the tumor or the tumor stage. The active component contains at least one chemotherapeutic substance. The coupling molecules are bound to the outside of the microbubbles and active substance molecules are likewise bound to the outside of the microbubbles or are enclosed by the microbubbles.